Heterogeneity Among Neutrophils

Marzena Garley1 · Ewa Jabłońska1

Abstract Neutrophils (PMNs) play a key role in innate defence mechanisms. Generally, PMNs were considered to have a homogeneous population of mature and diversified cells. It seems, however, that their pleiotropic action results from the existence of different subpopulations in this group of cells. There are data that confirm the involvement of PMNs in the direct activation of other cells in non-specific response, as well as specialised cells in specific response. For example, there have been observations of PMNs with different levels of activity in relation to lymphocytes, and a population was identified which had characteristics similar to those of cells which are capable of presenting antigens. There are also reports of PMNs which demonstrate different survival time or capacity for chemotaxis. Other studies suggest that the neutrophil response to *Staphylococcus aureus* is diverse (not identical among all neutrophil). There are also reports of PMNs with varying activity during inflammation, which might explain many as yet unknown pathophysiological aspects of their hyperreactivity. The functional dualism of PMNs in the course of neoplastic disorders raises a lot of controversy. This paper presents the current state of knowledge of the heterogeneity of PMNs and their potential roles in different stages of disease.

Keywords Neutrophils · PMNs · Heterogeneity · Subpopulations · Populations

Introduction

Neutrophils (PMNs: polymorphonuclear cells) for a long time were considered as fully differentiated effector cells of the inflammatory response. It was believed that their fundamental role was extracellular phagocytosis involving reactive oxygen species (ROS), cationic proteins and enzymes. In recent years, numerous studies have shown a wider range of functions these cells possess. Newly discovered effector molecule repertoire of neutrophils includes an array of cytokines, neutrophil extracellular traps and other molecules of innate humoral immunity. Neutrophils are involved in the activation and regulation of effector functions in other cells of the non-specific response, as well as of cells of specific immunity. It was confirmed that neutrophils play a key role in the pathogenesis of numerous disorder, from extra- and intracellular infections, such as chronic inflammation, autoimmunization or neoplastic disorders (Mantovani et al. 2011).

In light of this information, a question arises: do neutrophils form a heterogeneous cell population? Discoveries of new functions of leukocytes: lymphocytes, monocytes, were accompanied by indicating a new, specific population of cells with a characteristic antigen coat. Considering the wide range of neutrophil activities, it seems reasonable to look for subpopulations of these cells.

First Reports on Neutrophil Subpopulations

The search for neutrophil heterogeneity started in 1970–1980s. At the time research was focused on evaluating the functional differences of neutrophils, their density, and the biosynthesis of proteins/RNA (ribonucleic acid) (Broxmeyer et al. 1980; Harvath and Leonard 1982;
Neutrophils are an important element of the innate immune system, although recently their role as regulator and effector cells in innate immunity mechanisms is also recognised (Mócsai 2013; Nathan 2006; Németh and Mócsai 2012).

Puga et al. (2011) showed that there is a certain pool of neutrophils called B-cell helper neutrophils, found in the marginal zone of the spleen. These neutrophils manifest a capacity for producing significant amounts of cytokines, for example TNF superfamily proteins, such as B-cell

Neutrophil Populations with Different Survival Time

Survival of neutrophils has recently been the point of numerous scientific disputes. It is commonly agreed that human PMNs survive in blood for up to 8 h and then transfer into tissues, where they live for 1–2 days. Most recent reports indicate that neutrophil survival time may be significantly longer, lasting up to 90 h (Pillay et al. 2010). Longer lifespan of neutrophils may set the basis for PMNs to undergo phenotypic and functional changes and account for neutrophil heterogeneity (Silvestre-Roig et al. 2016).

It was found that there are subpopulations of human PMNs with a characteristic phenotype, showing the expression of HLA-DR (human leukocyte antigen DR), CD80, and CD49d molecules, which are characterised by a significantly extended survival of up to 72 h. These cells compose 8–17% of non-apoptotic neutrophils which produce significant amounts of superoxide anions and leukotrienes. Long-surviving neutrophils demonstrate an elevated phagocytic index and increased adhesion, as well as a limited capacity for chemotaxis and exocytosis of primary and secondary granules. Research has shown that stimulation of PMNs (isolated from human blood) with granulocyte–macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF)-α, and interleukin (IL)-4, all of which exist in inflammation sites, leads to generating long-living populations of neutrophils producing significant amounts of IL-8, IL-1 receptor antagonist, and IL-1β. The newly found subpopulation of human neutrophils is characterised by a unique profile of intracellular signalling molecule phosphorylation. Researches demonstrated an involvement of PI3K pathway kinases in extending the survival of identified neutrophil subpopulations. The results of these studies suggest that PMNs are capable of switching from a “classic” phenotype to a “long-living neutrophils” depending on the environmental conditions of the host (Chakravarti et al. 2009).

Under steady-state conditions, neutrophil heterogeneity may arise from ageing and replenishment by bone marrow–released neutrophils. Aged mouse neutrophils upregulate chemokine receptor 4 (CXCR4) and express low levels of β2-selectin. The aged subset has hypersegmented nucleus, reduced size and granularity (Casanova-Acebes et al. 2013; Rankin 2010; Zhang et al. 2015).

Hypothesis that different maturity levels of human PMNs contribute to different types of PMNs has not been unequivocally confirmed.
| Neutrophil subset          | Immunophenotype                                      | Functional properties                                      | References                                      |
|---------------------------|------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------|
| Mature/classic            | HNA-1 (FcγRIIIb, CD16)                              |                                                            | Bux (1999)                                      |
|                           | HNA-2 (CD177)                                        |                                                            |                                                 |
|                           | HNA-3 (CTL2)                                         |                                                            |                                                 |
|                           | HNA-4 (CD11b/CD18; Mac-1, CR3)                      |                                                            |                                                 |
|                           | HNA-5 (CD11a/CD18)                                  |                                                            |                                                 |
| Long-living               | HLA-DR, CD80, CD49d                                  | IL-8, IL-1Ra, IL-1β, NETosis                               | Chakravarti et al. (2009)                       |
| Aged                      | CD62L<sup>low</sup>CD49d<sup>high</sup>CD11B<sup>high</sup>CD49<sup>high</sup> | Phagocytosis, NETosis                                     | Casanova-Acebes et al. (2013), Rankin (2010), Zhang et al. (2015) |
| N<sub>Bth</sub>            | TCR<sup>+</sup>                                       | BAFF, APRIL                                               | Puga et al. (2011)                              |
| TCR<sup>+</sup>            | TCR<sup>αβ</sup>                                     | IL-8 inhibition of apoptosis                              | Puellmann et al. (2006)                         |
| PMN-I                     | TLR2/TLR4/TLR5/TLR8CD49d<sup>+</sup>CD11b<sup>+</sup> | IL-12, CCL3                                               | Tsada et al. (2004)                             |
| PMN-II                    | TLR2/TLR4/TLR7/TLR9CD49d<sup>-</sup>CD11b<sup>-</sup> | IL-10, CCL2                                               |                                                 |
| PMN-N                     | TLR2/TLR4/TLR9CD49d<sup>-</sup>CD11b<sup>-</sup>     |                                                            |                                                 |
| mPR3<sup>+</sup>           | mPR3<sup>high</sup>                                 | Outbreak or progression of chronic inflammatory           | Witko-Sarsat et al. (1999)                      |
| CD177                     | High, low, negative expression                      |                                                           | Wu et al. (2016)                                |
| LDNs                      | CD66b, CD11b<sup>-</sup>CD16<sup>+</sup> and/or CD11b<sup>low</sup>/CD16<sup>low</sup>. | Immunosuppressive                                         | Deng et al. (2016), Giallongo et al. (2015), Grayson et al. (2015), Hossain et al. (2015), Jiang et al. (2014), Liu et al. (2010), Mare et al. (2015), Marini et al. (2016), Midgley and Beresford (2016) |
| LDNs/G-MDSCs              | CD66bCD15<sup>+</sup>CD14<sup>-dim</sup>CD33<sup>dim</sup>HLA-DR<sup>-</sup> | Inhibition of T lymphocytes proliferation                 | Jiang et al. (2014), Mandruzzato et al. (2016), Solito et al. (2014) |
| LDGs                      | CD15<sup>+</sup>CD14<sup>low</sup>, CD10<sup>+</sup>CD14<sup>low</sup>, CD16<sup>high</sup>/CD86<sup>-</sup> | IFN-γ, TNF-α pro-inflammatory                           | Denny et al. (2010)                             |
| Bone marrow-derived immature neutrophils | CD10<sup>low</sup>-CD16<sup>low</sup> |                                                   | Manz and Boettcher (2014)                        |
| MDSCs                     | CD11b<sup>high</sup>CD62L<sup>dim</sup>/CD11b<sup>high</sup> | Inhibition of T lymphocytes proliferation                 | Pillay et al. (2012)                            |
| MDSCs in cancer           | CD14<sup>+</sup>CD33<sup>-</sup>HLA-DR<sup>-</sup>    | Inhibition of T lymphocytes function                      | Almand et al. (2001), Hoechst et al. (2008), Kusmartsev et al. (2008), Rodríguez et al. (2009) |
| N1                        | CD11b<sup>-</sup>/Ly6G<sup>-</sup>CD10<sup>-</sup>  | Anti-neoplastic activity                                 | Fridlender et al. (2009), Fridlender and Albelda (2012), Pekarek et al. (1995), Shen et al. (2007) |
| N2                        | CD11b<sup>-</sup>/Ly6G<sup>-</sup>                   | Pro-neoplastic properties                               | Jabłońska et al. (2012), Schmielau and Finn (2001), Tazawa et al. (2003) |
| Proangiogenic             | CXCR<sup>4</sup>VEGFR<sup>1</sup>                  | MMP-9                                                     | Christoffersson et al. (2012)                    |

*IL-1Ra* interleukin-1 receptor antagonist, *N<sub>Bth</sub>* B-cell helper neutrophils, *BAFF* B-cell activating factor, *APRIL* a proliferation-inducing ligand, *NETs* neutrophil extracellular traps
activating factor and a proliferation-inducing ligand, which have a strong effect on B lymphocyte proliferation and production of immunoglobulins (Puga et al. 2011).

Under certain conditions, neutrophils are able to take features of antigen-presenting cells, e.g., cross-presenting ovalbumin. It was observed that these cells absorb and present exogenous antigens, stimulating differentiation into cytotoxic lymphocytes through direct interaction between neutrophils and naive CD8⁺ T cells (Beauvillain et al. 2007; Pelletier et al. 2010).

Also, it was rather surprising to find a T-cell receptor zβ (TCRzβ receptor) on the surface of human neutrophils comprising a 5–8% subpopulation. Research showed that the expression of this receptor is accompanied by RAG1/ RAG2 recombinase. It was also found that expression of TCRzβ and the RAG1/RAG2 complex (recombination activating gene 1/2 complex) is regulated by G-CSF. Moreover, it was demonstrated that stimulation of this immunoreceptor in neutrophils results in increased secretion of IL-8 and inhibition of apoptosis. These findings were confirmed in experiments conducted on mice. The results include this subpopulation of neutrophils into the group of cells which demonstrate the features of innate immune response (Puellmann et al. 2006).

Neutrophil Population Diversity in Response to Staphylococcus aureus

Neutrophils play a key role in antibacterial response, which is confirmed by the high rate of bacterial infections in neutropenia patients. Nevertheless, despite correct or sometimes elevated levels of PMNs, it is possible to observe their dysfunction which may lead to sepsis.

Experimental tests provided evidence for the existence of two subpopulations of murine neutrophils with modified activity against Staphylococcus aureus and other, with a changed production of cytokines and chemokines, expression of Toll-like receptors (TLR), and different surface antigens and influence on macrophage activation. It was shown that one of these populations produces IL-12 and chemokine ligand 3 (CCL3; and is called PMN-I), while the other secretes IL-10 and CCL2 (PMN-II), compared to the normal neutrophil population (so-called PMN-N). PMN-I population activates macrophages typically (with the involvement of CCL5 and inducible isofrm of nitric oxide synthase) and PMN-II performs it in an alternative manner (with the involvement of CCL17 and a mannose receptor), yet PMN-N do not activate macrophages. Cells from the PMN-I population indicate the expression of TLR2/TLR4/TLR5/TLR8, PMN-II cells indicate the expression of TLR2/TLR4/TLR7/TLR9, and PMN-N cells express TLR2/TLR4/TLR9. Also, PMN-I indicate the expression of surface antigens: CD49d⁺CD11b⁺, PMN-II: CD49d⁻CD11b⁺, PMN-N: CD49d⁻CD11b⁻. PMN-I cells were obtained from animals resistant to methicillin-resistant S. aureus (MRSA), while MRSA-sensitive mice were the source of the second group of PMNs. Some authors believe that PMN-Ns obtained from naive mice might differentiate into certain populations of neutrophils under the influence of specific factors, such as infection (Tsuda et al. 2004).

Infection or aseptic inflammation is the main postoperative complications. It was believed that such complications may result from the use of polyethylene components or be caused by the release of ultra-high-molecular-weight polyethylene (UHMWPE) from, for example, orthopaedic prostheses. To confirm this thesis, isolated human neutrophils were incubated in vitro with UHMWPE molecules and then added to S. aureus cultures. Surprisingly, the cells responded in different manners. It was shown that over 40% of PMNs which absorbed UHMWPE lost the capacity for bacterial phagocytosis. An inhibited bacterium capture was observed in neutrophils exposed to UHMWPE, but also the cells showed an increased respiratory burst. Almost 30% of the PMNs did not contain any UHMWPE molecules, and most of them were capable of absorbing S. aureus cells. These findings indicate, firstly, that there are different subpopulations amongst PMNs and, secondly, they explain the cause of complications related to pyogenic infections associated with biomedical implants (Bernard et al. 2007).

Neutrophil Populations with Different Activity in Inflammation

Many aspects of the pathophysiology of neutrophil hyperreactivity and its role in immune disorders remain largely unknown. Perhaps identifying and describing the populations of neutrophils associated with inflammation might serve in explaining these issues.

Research conducted by Witko-Sarsat et al. (1999) showed that circulating neutrophils form two populations of cells based on the presence or lack of a membrane expression of proteinase 3 (mPR3). It was found that the percentage of mPR3⁺ differs in healthy subjects. Also, it was observed that a large ratio of mPR3⁺ neutrophils among circulatory leukocytes may be a significant factor of an outbreak or progression of chronic inflammatory disorders. This is indicated by an increased number of mPR3high neutrophils in patients with vasculitis and rheumatoid arthritis (Witko-Sarsat et al. 1999).

Other studies looked for co-expression of mPR3 and CD177 molecules, as an effect of cell activation. The authors found CD177 in the population of mPR3⁺
neutrophils. Experiments showed an analogous increase or
decrease of the examined molecules during cell stimulation
or in the course of spontaneous apoptosis. According to
researchers, the source of mPR3 lies in secondary granules
and excretory vesicles, as in the case of CD177. PR3 is an
important molecule in the course of Wegener’s granulo-
matosis, which is characterised by an increased level of
mPR3 \( \text{CD}177^+ \) neutrophil subpopulation (Bauer et al.
2007). CD177, in humans, is exclusively expressed on the
surface of PMNs and regulates transmigration across the
endothelium (Sachs et al. 2007). CD177 expression is
required for surface presentation of PR3, which facilitates
the transmigration of CD177\(^+\) neutrophils (Kuckleburg
et al. 2012; von Vietinghoff et al. 2007). Membrane PR3
was identified as an antigen ANCA (anti-neutrophil cyto-
plasmic antibody)-dependent vasculitis (Jennette et al.
1990). The expression of CD177 may vary in PMNs and in
different individuals (e.g., high, low, negative expression)
(Wu et al. 2016). Implication of CD177\(^+\) or CD177\(^-\)
populations in ANCA-derived vasculitis or other inflam-
matory diseases remain unknown (Xie et al. 2015). The
absence of CD177 did not affect the migratory capacity of
neutrophils but it caused cell death (Sachs et al. 2007; Xie
et al. 2015).

**Subpopulations of PMNs in Low Density**

Centrifugation of blood in the density gradient allows the
isolation of two leukocyte fractions: low density cells—
peripheral blood mononuclear cells (PBMCs) and higher
density cells—PMNs.

Low-density neutrophils (LDNs) are found to sediment
within the PBMC fraction obtained after density gradient
centrifugation of blood from patients with cancer or
inflammation (Scapini et al. 2016). LDNs display a neu-
rophil-like morphology and express CD66b, but can be
heterogeneous. During inflammatory condition they can be
composed of mixed populations of both CD11b\(^+\)/CD16\(^-\)
mature and immature CD11b\(^{low/–}\) and/or CD16\(^{low/–}\) and
their frequency often correlates with disease severity and/
or responsiveness to treatment (Deng et al. 2016; Grayson
et al. 2015; Hossain et al. 2015; Jiang et al. 2014; Liu et al.
2010; Mare et al. 2015; Midgley and Beresford 2016). Why
only a group of normal density mature neutrophils become
LDNs upon activation remains unknown.

Immunosuppressive LDNs, known as granulocytic
myeloid-derived suppressor cells (G-MDSCs), have been
discovered within the PBMCs fraction from patients with
solid tumours, hematological malignancies and inflamma-
tory disease conditions (Darcy et al. 2014; Favaloro et al.
2014; Giallongo et al. 2015; Gorgun et al. 2013; Janols
et al. 2014; Marini et al. 2016; Rieber et al. 2014). LDNs/
G-MDSCs suppress proliferation of T cells and/or inter-
feron (IFN)-\(\gamma\) production and are described as
CD66b\(^+\)/CD15\(^-\)/CD14\(^{dim}\)/CD33\(^{dim}\)/HLA-DR\(^+\) cells (Man-
druzzato et al. 2016; Solito et al. 2014). They may also
express enhanced/reduced levels of maturation markers
(CD11b, CD16, CD124/IL-4R), activation markers
[CD66b, CD16, CD11b, CD62L, CD54/ICAM-1 (inter-
cellular adhesion molecule 1), CD63, CD274/PD-L1
(programmed death-ligand 1)], functional markers (argi-

tase 1) or chemokine receptors (CXCR2, CXCR4)
(Scapini et al. 2016).

There are also bone marrow-derived immature PMNs,
revealed as CD10\(^low/–\)/CD16\(^low/–\) cells, mobilised during
severe systemic infections (Manz and Boettcher 2014).
Other tests identified a population of mature human neu-

trophils with a CD11b\(^{bright}\)/CD62L\(^{dim}\)/CD11b\(^{bright}\)/
CD16\(^{bright}\) antibody coat as a unique, circulating population
of myeloid cells (MDSC) capable of suppressing the pro-

liferation of human T cells. These cells were found in
patients with inflammation. Some researchers claim that
the mechanism of inhibiting the proliferation of T lympho-
cytes depends on the expression of Mac-1 integrin
(macrophase 1 antigen) and ROS released to the immune
synapse between PMNs and T cell, which may be the target
of modulation strategies of this phenomenon (Pillay et al.
2012).

The presence of proinflammatory LDNs, called low-
density granulocytes (LDGs), was reported in blood from
patients with inflammatory conditions (Scapini et al. 2016).
Different data presented by Denny et al. (2010) showed that
in the mononuclear leukocyte fractions isolated by
density gradient centrifugation of blood taken from patients
with systemic lupus erythematosus, there is a characteristic
proinflammatory neutrophil subpopulation, identified as
CD15\(^+\)/CD14\(^{low}\), CD10\(^+\)/CD14\(^{low}\), CD16\(^{high}\)/CD86\(^+\) pheno-
type cells. These neutrophils release increased amounts
of type I interferons and IFN-\(\gamma\), as well as TNF-\(\alpha\), yet they
also demonstrate decreased phagocytosis. Moreover, LDGs
induce endothelial cell destruction and interfere with its
reconstruction processes (Denny et al. 2010). Perhaps the
evaluation of the proinflammatory neutrophil subpopula-
tion fractions would prove useful in diagnosing and
monitoring inflammatory diseases.

**Neutrophil Heterogeneity in the Neoplastic Process**

In recent years, it has been speculated whether tumor cells
are able to influence the maturation and differentiation
of myeloid cells and, in consequence, change the course of
the immune response. Tumor-implanted mice indicated the
presence of immunosuppressive PMNs and monocytes,
named MDSC, which were found to inhibit the function of
T lymphocytes (Ostrand-Rosenberg and Sinha 2009). It is possible, that MDSCs are produced in the bone under the influence of a substance secreted by the tumor cells. Researchers looked for similar cells in cancer patients. It was found that activated granulocytes in neoplastic patients exhibit similar features to mice MDSC. Others suggest that populations of CD14$^+$ cells might be the equivalent of MDSC. Results of other researchers indicate speculate that the CD33$^-$ and HLA-DR-negative markers characterise human MDSC (Almand et al. 2001; Hoechst et al. 2008; Kusmartsev et al. 2008; Rodriguez et al. 2009).

Studies of large groups of head and neck, lung, and urinary tract cancer showed the presence of a large number of MDSC and neutrophils at different maturity stages. These neutrophils demonstrated suppressive properties against T cells, such as inhibition of proliferation and production of IFN-$\gamma$. Also, immature granulocytes from the MDSC population possessed reduced capacity for migration and chemotaxis (lack of CXCR1 and CXCR2 receptors), limited function (decreased production of ROS and IL-8), and extended lifespan (Brandau et al. 2011).

Current knowledge about neutrophils suggests that the so-called tumor-associated neutrophils (TANs) and, according to some authors, their precursors (peripheral neutrophils G-MDSC) found in the spleen, bone marrow, and blood play a key role in cancer biology. Still, the results of micro-array studies clearly showed that TANs are a separate neutrophil population from G-MDSC or regular neutrophils (Fridlender and Albelda 2012). However, the role of TANs in response to cancer remains a controversial subject (Fig. 1; Table 2).

The explanation of the functional dualism of PMNs may be found in the existence of subpopulations of these cells with varying immune properties. It is suggested to divide TANs into N1 and N2. The N1 phenotype is characterised with anti-neoplastic activity, contrary to N2 cells which promote tumor development (Galdiero et al. 2013; Granot and Jablonska 2015; Kobayashi 2015). N1 cells show elevated expression of immunoactive cytokines and chemokines, a lower level of arginase, and a wider capacity for killing neoplastic cells in vitro (Pekarek et al. 1995; Shen et al. 2007). N1 neutrophils promote the recruitment and activation of CD8$^+$ T cells through the production of CCL-3, CXCL9, CXCL10 and proinflammatory cytokines such as IL-12, TNF-$\alpha$ and GM-CSF (Fridlender and Albelda 2012). It was also found that the neutrophil–CD8$^+$ interaction is crucial in the course of the anticancer immune response, as the lack of neutrophils in the reaction site effectively reduces the response by CD8$^+$ T cells (Suttman et al. 2006).

Pro-neoplastic properties of the N2 phenotype cells are associated with the production of proangiogenic and...
growth factors (e.g., VEGF: vascular endothelial growth factor), as well as enzymes degrading the extracellular matrix (e.g., MMP-9: matrix metalloproteinase 9). It is also believed that TANs/N2 are capable of inhibiting the immune response against cancer cells by influencing the activity of other cells (Jabłon’ska et al. 2012; Schmielau and Finn 2001; Tazawa et al. 2003).

Currently attempts are being made at determining the factors that influence the differentiation of cells into N1 and N2 populations. It was established that transforming growth factor (TGF)-β is important in switching the TANs phenotype. Fridlender et al. (2009) indicated that blocking TGF-β significantly slows down the growth of the neoplastic process through the activation of CD8+ T cells and macrophages. Moreover, the inactivity of TGF-β results in increased amounts of chemokines for PMNs and, consequently, the recruitment of murine CD11b$^+$/Ly6G$^+$ TANs with hypersegmented nuclei, elevated cytotoxicity, and high expression of proinflammatory cytokines. The results of these studies indicate that the presence of TGF-β in the neoplasm microenvironment induced the activity of N2 TANs population with a pro-neoplastic phenotype (Fridlender et al. 2009).

According to other authors, the switch between N1 and N2 TANs phenotype is connected with advancement stage of the disease. Their findings indicated that TANs isolated from the lungs of patients with early-stage cancer do not demonstrate immunosuppressive properties but rather stimulate the immune response (Eruslanov et al. 2014).

Proangiogenic Neutrophil Populations in Response to Transplants

Despite numerous evidence confirming the existence of neutrophil subpopulations, the opponents of the thesis suggest that neutrophils are highly “flexible” cells which allow them to adapt to the environment. The results obtained by Christoffersson et al. (2012) prove that there are two distinct populations of two distinct populations before moving to the tissue, in place of the immune response. The authors discovered a proangiogenic population of PMNs with a high level of CXCR4, recruited at the transplantation location by VEGF-A and releasing MMP-9, enabling the revascularization of the transplanted tissue. The use of VEGF-A or macrophage inflammatory protein 2 to induce this phenotype of PMNs did not produce the expected result, suggesting that this subpopulation of two distinct populations exists even before the contact with the reaction site (Christoffersson et al. 2012).

Conclusion

This article is to draw the reader’s attention to the difficulty in assessing the heterogeneity of PMNs. The authors of different studies suggest the variable role of neutrophils in depending on conditions. Therefore, it is difficult to determine the classic phenotype of PMNs on the basis of current knowledge about these cells.

Table 2 Properties of neutrophils differing neutrophils populations, by Fridlender and Albelda (2012)

|                  | Naive neutrophils | G-MDSC | TANs |
|------------------|------------------|--------|------|
| Granule proteins |                  |        |      |
| Primary          | +++              | +      | +    |
| Secondary        | +++              | Mod    | +    |
| Tertiary         | +++              | Mod    | +    |
| Respiratory burst|                  |        |      |
| Peroxidase       | +++              | +++    | +    |
| Reduced nicotinamide adenine dinucleotide phosphate complex | +++ | Mod | + |
| TLR              | +                | +++    | Mod  |
| Structural genes |                  |        |      |
| Actin binding    | Mod              | Mod    | +    |
| Cytoskeleton     | Mod              | Mod    | +    |
| Apoptosis        |                  |        |      |
| Intrinsic (BCL2) pathway | Mod | +++ (BH-3) | + |
| NF-κB-antiapoptotic | +++          | +      | +    |
| Immune system    |                  |        |      |
| Chemokines       | +                | Mod    | +++  |
| Cytokine activity| +                | Mod    | +++  |
| APC genes        | +                | +++    | +++  |

+++ high, + low, Mod moderate
Based on the above information, it may well be assumed that the wide scope of activity attributed to neutrophils is connected with the existence of different subpopulations of these cells. Perhaps the pleiotropic activity of neutrophils is connected with the level of differentiation, which largely depends on the cytokine microenvironment and the current need for specific phenotype cells, and therefore, a specific function. Research conducted to identify neutrophil subpopulations must be continued as more and more questions arise about the multitude of functions of these cells. Exploring knowledge about the different, and sometimes even contradictory, aspects of neutrophil biology once be used as a therapeutic instrument in the treatment of disorders which involve neutrophils.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Almand B, Clark JI, Nikitina E et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689
Bauer S, Abdgawad M, Gunnarsson L et al (2007) Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol 81:458–464
Beauvillain C, Delneste Y, Scotet M et al (2007) Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110:2965–7329
Bernard L, Vaudaux P, Huggler E et al (2007) Inactivation of a subpopulation of human neutrophils by exposure to ultrahigh-molecular-weight polyethylene wear debris. FEMS Immunol Med Microbiol 49:425–432
Brandau S, Trellakis S, Bruderek K et al (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311–317
Brown CC, Malech HL, Gallin JI (1989) Intravenous endotoxin recruits a distinct subset of human neutrophils, defined by monoclonal antibody 31D8, from bone marrow to the peripheral circulation. Cell Immunol 123:294–306
Broxmeyer HE, Ralph P, Bognacki J et al (1980) A subpopulation of human polymorphonuclear neutrophils contains an active form of lactoferrin capable of binding to human monocyes and inhibiting production of granulocyte-macrophage colony stimulatory activities. J Immunol 125:903–909
Bux J (1999) Nomenclature of granulocyte antigens. Transfusion 39:662–663
Casanova-Acebes M, Pitaval C, Weiss LA et al (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. Cell 153:1025–1035
Chakravarti A, Rusu D, Flamand N et al (2009) Reprogramming of a subpopulation of human blood neutrophils by prolonged exposure to cytokines. Lab Invest 89:1084–1099
Chollet-Martin S, Montravers P, Gibert C et al (1992) Subpopulation of hyperresponsive polymorphonuclear neutrophils in patients with adult respiratory distress syndrome. Role of cytokine production. Am Rev Respir Dis 146:990–996
Christoffersson G, Vågesjö E, Vandooren J et al (2012) VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 120:4653–4662
Clement LT, Lehmeyer JE, Garland GL (1983) Identification of neutrophil subpopulations with monoclonal antibodies. Blood 61:326–332
Darcy CI, Minigo G, Piera KA et al (2014) Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care 18:R163
Deng Y, Ye J, Luo Q et al (2016) Low-density granulocytes are elevated in mycobacterial infection and associated with the severity of tuberculosis. PLoS One 11:e0153567
Denny MF, Yalavarthi S, Zhao W et al (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 184:3284–3297
Erulusanov EB, Bhojnagarwala PS, Quatromoni JG et al (2014) Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest 124:5466–5480
Favoloro J, Ljyadipitya T, Brown R et al (2014) Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 55:2893–2900
Frieldenger ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Cancerogenesis 33:949–955
Frieldenger ZG, Sun J, Kim S et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16:183–194
Galdiero MR, Bonavita E, Barajon I et al (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402–1410
Gallin JI (1984) Human neutrophil heterogeneity exists, but is it meaningful? Blood 63:977–983
Giallongo C, Panninello N, Brundo MV et al (2015) Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol 5:107
Gornun QT, Whitehill G, Anderson JL et al (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 12:2975–2987
Granot Z, Jablonska J (2015) Distinct functions of neutrophil in cancer and its regulation. Mediat Inflamm 2015:701067
Grayson PC, Carmona-Rivera C, Xu L et al (2015) Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 67:1922–1932
Harvath L, Leonard EJ (1982) Two neutrophil populations in human blood with different chemotactic activities: separation and re-population. J Leukoc Biol 35:234–243
Hoskins DM, Pal SK, Moreira D et al (2015) TLR9-Targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res 21:3771–3782
Jabłońska E, Wawrusiewicz-Kuryłonek N, Garley M et al (2012) A proliferation-inducing ligand (APRIL) in neutrophils of patients with oral cavity squamous cell carcinoma. Eur Cytokine Netw 23:93–100

Janols H, Bergenfelz C, Allauoi R et al (2014) A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol 96:685–693

Jennette JC, Hoidal JR, Falk RJ (1990) Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 75:2263–2264

Jiang J, Guo W, Liang X (2014) Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. Hum Immunol 75:1128–1137

Klempner MS, Gallin JI (1978) Separation and functional characterization of human neutrophil subpopulations. Blood 51:659–669

Kobayashi Y (2015) Neutrophil biology: an update. EXCLI J 14:220–227

Kuckelburg CJ, Tilkens SB, Santoso S et al (2012) Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils. J Immunol 188:2419–2426

Kusmartsev S, Su Z, Heiser A et al (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270–8278

Liu CY, Wang YM, Wang CL et al (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14+/CD15+CD33+ myeloid-derived suppressor cells and CD8−T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136:35–45

Mandruzzato S, Brandau S, Britten CM et al (2016) Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother 65:161–169

Mantovani A, Cassatella MA, Costantini C et al (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531

Manz MG, Boettcher S (2014) Emergency granulopoiesis. Nat Rev Immunol 14:302–314

Marc TA, Treacher DF, Shankar-Hari M et al (2015) The diagnostic and prognostic significance of monitoring blood levels of immature neutrophils in patients with systemic inflammation. Crit Care 19:57

Marini O, Spina C, Mimiola E et al (2016) Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget 7:27676–27688

McCormack RT, Nelson RD, Chenoweth DE et al (1987) Identification and characterization of a unique subpopulation (CALLA/CD8−) of human neutrophils manifesting a heightened chemotactic response to activated complement. Blood 70:1624–1629

Midgley A, Beresford MW (2016) Increased expression of low density granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66:4756–4760

Möcsai A (2013) Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 210:1283–1299

Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6:173–182

Németh T, Möcsai A (2012) The role of neutrophils in autoimmune diseases. Immunol Lett 143:9–19

Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4490–4506

Pekarek LA, Starr BA, Toledano AY et al (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181:435–440

Pelletier M, Maggi L, Michielti A et al (2010) Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115:335–343

Pember SO, Kinkade JM Jr (1983) Differences in myeloperoxidase activity from neutrophilic polymorphonuclear leukocytes of differing density: relationship to selective exocytosis of distinct forms of the enzyme. Blood 61:1116–1124

Pember SO, Barnes KC, Brandt SJ et al (1983) Density heterogeneity of neutrophilic polymorphonuclear leukocytes: gradient fractionation and relationship to chemotactic stimulation. Blood 61:1105–1115

Pillay J, den Braber I, Vrisekoop N et al (2010) In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116:625–627

Pillay J, Kamp VM, van Hoffen E et al (2012) A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 122:327–336

Puellmann K, Kaminski WE, Vogel M et al (2006) A variable immunoreceptor in a subpopulation of human neutrophils. Proc Natl Acad Sci USA 103:14441–14446

Puga I, Cols M, Barra CM et al (2011) B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 13:170–180

Ramsey WS (1972) Analysis of individual leucocyte behavior during chemotaxis. Exp Cell Res 70:129–139

Rankin SM (2010) The bone marrow: a site of neutrophil clearance. J Leukoc Biol 88:241–251

Rieber N, Wecker I, Neri D et al (2014) Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GrHD. Bone Marrow Transplant 49:543–552

Rodriguez PC, Ernesto MS, Hernandez C et al (2009) Arginase-I-producing myeloid-derived suppressor cells in renal cancer are a population of activated granulocytes. Cancer Res 69:1553–1560

Sachs UJ, Andrei-Selmer CL, Maniar A et al (2007) The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem 282:23603–23612

Scapini P, Marini O, Tecchio C et al (2016) Human neutrophils in the saga of cellular heterogeneity: insights and open questions. Immunol Rev 273:48–60

Schmieleau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756–4760

Seligmann B, Chused TM, Gallin JI (1981) Human neutrophil heterogeneity identified using flow microfluorometry to monitor membrane potential. J Clin Invest 68:1125–1131

Shen L, Smith JM, Shen Z et al (2007) Inhibition of human neutrophil degranulation by transforming growth factor-beta1. Clin Exp Immunol 149:155–161

Silvestre-Roig C, Hidalgo A, Soehnlein O (2016) Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood 127:2173–2181

Solito S, Marigo I, Pinton L et al (2014) Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319:47–65

Suttmann H, Riemsbergsber J, Bentien G et al (2006) Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66:8250–8257

Tazawa H, Okada F, Kobayashi T et al (2003) Infiltration of neutrophilic polymorphonuclear leukocytes in sepsis patients, with the granulocytic subtype differing density: relationship to selective exocytosis of distinct forms of the enzyme. Blood 61:1116–1124

Tazawa H, Okada F, Kobayashi T et al (2003) Infiltration of neutrophilic polymorphonuclear leukocytes: gradient fractionation and relationship to chemotactic stimulation. Blood 61:1105–1115

Tazawa H, Okada F, Kobayashi T et al (2003) Infiltration of neutrophilic polymorphonuclear leukocytes: gradient fractionation and relationship to chemotactic stimulation. Blood 61:1105–1115

Tsuda Y, Takahashi H, Kobayashi M et al (2004) Three different neutrophil subsets exhibited in mice with different
susceptibilities to infection by methicillin-resistant *Staphylococcus aureus*. Immunity 21:215–226
von Vietinghoff S, Tunnemann G, Eulenberg C et al (2007) NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 109:4487–4493
Witko-Sarsat V, Lesavre P, Lopez S et al (1999) A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 10:1224–1233

Wu Z, Liang R, Ohnesorg T et al (2016) Heterogeneity of human neutrophil CD177 expression results from CD177P1 pseudogene conversion. PLoS Genet 12:e1006067
Xie Q, Klesney-Tait J, Keck K et al (2015) Characterization of a novel mouse model with genetic deletion of CD177. Protein Cell 6:117–126
Zhang D, Chen G, Manwani D et al (2015) Neutrophil ageing is regulated by the microbiome. Nature 525:528–532